Acquisitions in pharmaceutical industry staying at an elevated paceStrong balance sheet even before having any drugs approved for salePromising lentiviral genetic treatment platformSignificant … [Read more...] about Acquisition Targets: Could Bluebird Be In Season?
Introduction Bristol-Myers Squibb (NYSE: BMY) is a profitable global bio-pharmaceutical company targeting an array of serious diseases and unmet medical needs. Earlier this month BMY announced … [Read more...] about Bristol-Myers Squibb Positioned For Deep Penetration In the Multiple Myeloma Market
Leave a comment and click here to sub for MS article alerts and our newsletter! Overview January 14th, the FDA approved cabozantinib (CABOMETYX) for the treatment of hepatocellular carcinoma (HCC) in … [Read more...] about FDA Approves Cabozantinib; But it’s Not Alone
LEAVE A COMMENT AND CLICK HERE TO SUBSCRIBE FOR MS ARTICLE ALERTS AND OUR NEWSLETTER! Adma Biologics (Nasdaq: ADMA) announced today filing of supplementary information to the FDA in … [Read more...] about MS Monday Update-ADMA, CELG
Leave a comment and click here to subscribe for MS article alerts and our newsletter! MRK Exercises Option For NGM Bio's Investigational Insulin Sensitizer-NGM313 January 3rd, 2019 MRK … [Read more...] about MS Morning Update
Overview Galectin Therapeutics (NASDAQ GALT $5.96) is a leader in the development of a treatment for Non-Alcoholic SteatoHepatitis, an unmet medical need worth billions. Their star drug … [Read more...] about GALT is Primed for Acquisition or Partnership